{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T02:12:00Z","timestamp":1717553520208},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.hrtlng.2007.10.002","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T21:18:20Z","timestamp":1206479900000},"page":"153-156","source":"Crossref","is-referenced-by-count":7,"title":["Adult respiratory distress syndrome after treatment with pegylated interferon \u03b1-2a and ribavirin"],"prefix":"10.1016","volume":"37","author":[{"given":"Edmond","family":"Vartany","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cary A.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence K.","family":"Trow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.hrtlng.2007.10.002_bib1","doi-asserted-by":"crossref","first-page":"112S","DOI":"10.1002\/hep.510260720","article-title":"Side effects of alpha interferon in chronic hepatitis C","volume":"26","author":"Dusheiko","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib2","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1378\/chest.106.2.612","article-title":"Interferon-related bronchiolitis obliterans organizing pneumonia","volume":"106","author":"Ogata","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib3","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1111\/j.1572-0241.2003.08183.x","article-title":"Eosinophilic pneumonitis secondary to pegylated interferon alpha-2b and\/or ribavirin therapy","volume":"98","author":"Hoffman","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1378\/chest.105.3.939","article-title":"Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C","volume":"105","author":"Chin","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0190-9622(96)90350-3","article-title":"Interferon alfa-induced interstitial pneumonitis in a patient with cutaneous T-cell lymphoma","volume":"35","author":"Nouri","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib6","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1183\/09031936.96.09122691","article-title":"Pneumonitis during interferon and\/or herbal drug therapy in patients with chronic active hepatitis","volume":"9","author":"Ishizaki","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/15563659709001177","article-title":"Alpha-interferon induced severe pneumonitis","volume":"35","author":"Wolf","year":"1997","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00000441-200110000-00015","article-title":"Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection","volume":"322","author":"Karim","year":"2001","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib9","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1111\/j.1572-0241.2002.05999.x","article-title":"Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C","volume":"97","author":"Kumar","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1378\/chest.124.1.406","article-title":"Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS","volume":"124","author":"Abi-Nassif","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib11","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0168-8278(98)80357-7","article-title":"Sarcoidosis associated with interferon alpha therapy for chronic hepatitis C","volume":"28","author":"Hoffman","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1378\/chest.116.2.569","article-title":"Interferon-alpha therapy associated with the development of sarcoidosis","volume":"116","author":"Pietropaoli","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archderm.141.7.865","article-title":"Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C","volume":"141","author":"Hurst","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib14","first-page":"1431","article-title":"Pleural effusion during interferon treatment for chronic hepatitis C","volume":"47","author":"Takeda","year":"2000","journal-title":"Hepatogastoenterol"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4065\/74.4.367","article-title":"Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C","volume":"74","author":"Bini","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988-1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib18","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib19","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11894-001-0038-z","article-title":"Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?","volume":"3","author":"Schiffman","year":"2001","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrtlng.2007.10.002_bib22","unstructured":"The IDEAL study, Individualized Dosing Efficacy vs. flat dosing to Assess optimaL pegylated interferon. Available at: http:\/\/www.idealstudy.com."},{"key":"10.1016\/j.hrtlng.2007.10.002_bib23","series-title":"Product information: PEG-Intron \u00ae, peginterferon alpha2b","year":"2001"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956307001781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956307001781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T08:11:44Z","timestamp":1539677504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956307001781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0147956307001781"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2007.10.002","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}